Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand Licenses Four Programs to Seelos Therapeutics

Read More

Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.

Read More

Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes

Read More

Recent Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range